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Research in Translation
T
he human immune system is 
extraordinarily active against 
infection with HIV-1, yet never 
eliminates the virus and rarely controls 
viral replication for prolonged periods 
without the assistance of anti-retroviral 
therapy (ART). In order to harness the 
power of the human immune response 
in HIV therapy, we need a better 
understanding of the key elements of 
protective immunity against the virus 
and how and why these ultimately fail 
in chronic infection.
A New Study on Cytotoxic T 
Lymphocytes
Most investigators would nominate 
cytotoxic T lymphocytes (CTLs) as 
key players in the control of HIV-1 
infection, based on data accumulated 
over the two decades since they were 
ﬁ  rst described. This evidence includes 
the appearance of CTLs very early 
in HIV-1 infection coinciding with a 
profound drop in plasma viral load and 
the dramatic rise in viraemia following 
CTL depletion in monkey models of 
both acute and chronic infection with 
simian immunodeﬁ  ciency virus [1]. 
In a new study in this issue of PLoS 
Medicine, Marcus Altfeld and colleagues 
describe the fate of CTLs responding 
to HIV-1 from the very earliest stages 
of infection—the time that most 
investigators believe is critical in 
determining the long-term outcome 
of HIV-1 infection [2]—through 
the transition to chronic infection 
[3]. Although the functionality and 
phenotype of HIV-speciﬁ  c CTLs 
showed variability both between and 
within patients, deterioration in the 
number of functions attributable to 
each individual T cell was consistently 
found in untreated patients. Thus in 
the 11 out of 18 patients who chose 
not to start ART in acute infection, 
the capacity of HIV-speciﬁ  c CTLs to 
secrete a range of anti-viral cytokines 
and chemokines as well as to generate 
cytotoxic granules in response to 
an encounter with HIV antigens 
declined in the face of continuing viral 
replication. 
Deterioration of immune function as 
viral levels increase is well described at 
other stages of HIV-1 infection, but it is 
inevitably difﬁ  cult to determine which 
is cause and effect in this scenario. In 
this new study, the authors were able to 
exploit another observation to examine 
the underlying causes of declining 
T cell function in their patients. By 
studying the evolution of the infecting 
virus in the ﬁ  rst months of infection, 
they noted that in many instances there 
was an early accumulation of mutations 
in T cell epitopes that enabled the virus 
to avoid recognition by circulating 
CTLs. Not only did these mutations 
render virus-infected cells “invisible” 
to the responding T cells, but they also 
prevented repeated stimulation of the 
cells following contact with their target 
antigen. Even in untreated patients, 
the effect of removing CTLs from 
antigen exposure led to a very similar 
preservation of T cell function to that 
seen in those with a good response 
to ART. This maintenance of CTL 
function was particularly striking in 
untreated patients, for whom escape 
mutations were generated to some 
but not all of their repertoire of 
responding CTLs, thereby making it 
possible to discern the role of repeated 
antigenic stimulation in promoting T 
cell dysfunction. 
These observations are also 
important in highlighting how 
early in HIV-1 infection immune 
pressure from CTLs can drive the 
emergence of escape mutations: this 
is well documented in the macaque 
model [4], but has not been studied 
systematically in human infection. CTL 
escape mutations were selected in nine 
of the untreated patients in Altfeld 
and colleagues’ study and could be 
detected as early as 61 days after initial 
presentation.
Clinical Implications of the Study
What are the clinical implications 
of this study? If polyfunctional HIV-
speciﬁ  c CTLs need to be preserved 
long term for the ﬁ  ght against HIV-1 
infection, then this study suggests that 
such preservation is best achieved by 
suppressing HIV-1 replication both 
early and efﬁ  ciently. The question of 
whether or not to start ART in acute 
HIV-1 infection has been controversial. 
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Marcus Altfeld and colleagues suggest 
that the exhaustion of virus-speciﬁ  c CD8+ 
T cells during chronic HIV infection likely 
results from the persistence of antigen.PLoS Medicine  |  www.plosmedicine.org 0722 May 2008  |  Volume 5  |  Issue 5  |  e103
Acute HIV-1 infection is 
characterised by high levels of viral 
replication, dissemination of virus to 
lymphoid tissue reservoirs, and gradual 
depletion of circulating HIV-1–speciﬁ  c 
CD4+ T lymphocytes [5,6]. Evidence 
from the study of gut-associated 
lymphoid tissue (GALT) in animal 
models suggests that there is massive 
infection of memory CD4+ T cells in 
GALT and subsequent loss of over half 
the total memory T cell pool within 
two weeks of experimental simian 
immunodeﬁ  ciency virus infection [7]. 
If this situation is mirrored in human 
infection, as suggested by the extensive 
depletion of GALT T cells in biopsies 
taken in chronic HIV-1 infection 
[8], the implication is that very early 
intervention would be needed to 
preserve memory T cell function. 
Although the use of ART in chronic 
HIV infection undoubtedly results in 
signiﬁ  cant reductions in morbidity and 
mortality, reconstitution of the host 
immune system is rarely achieved. For 
example, HIV-speciﬁ  c CD4+ T helper 
cell responses, which crucially augment 
effector HIV-speciﬁ  c CD8+ responses, 
are poorly restored by ART in chronic 
infection [9,10]. Taken together, these 
data lead to the inevitable question 
of whether starting ART in acute HIV 
infection, and thereby minimising 
virus dissemination and damage to 
mucosal-associated lymphoid tissue, 
could facilitate the development and 
preservation of enhanced HIV-speciﬁ  c 
immunity and thus favourably alter the 
future course of disease. 
Slow restoration of a polyfunctional 
CTL phenotypic proﬁ  le similar to that 
observed by Altfeld and colleagues 
can also be achieved in chronic HIV-
infected patients treated with ART 
[11]. However, the clinical signiﬁ  cance 
of this improvement remains unclear 
in the face of evidence that suggests 
cessation of ART during treatment 
interruption in chronic HIV-1 infection 
results in rapid viral rebound and no 
long-term change in viral set point 
[12]. HIV-speciﬁ  c CTLs with strong ex 
vivo proliferative capacity are a feature 
of HIV long-term non-progressors [13], 
and can also be detected in acutely 
HIV-infected patients during the peak 
of viraemia, but gradually diminish 
during the ﬁ  rst year of infection in the 
absence of therapy [14]. Preservation 
of CTL proliferative capacity and 
effector function appears to be critically 
dependent on interleukin-2 (IL-2) 
production from HIV-speciﬁ  c CD4+ T 
cells [14]; this production in turn can 
be preserved by early institution of ART 
[15]. 
Structured Treatment 
Interruptions
Clinicians have been understandably 
reluctant to commit patients diagnosed 
with acute HIV-1 infection to lifelong 
ART. An alternative strategy was based 
on the hypothesis that preservation 
of HIV-speciﬁ  c immunity could be 
achieved by starting ART in acute 
infection, followed by structured 
treatment interruptions (STIs), thereby 
allowing “immune boosting” by 
exposure to autologous virus. 
This strategy involved restarting 
therapy if rebound plasma viraemia 
increased above set thresholds (more 
than 5,000 copies/ml for three 
consecutive weeks or more than 50,000 
copies/ml on one occasion) and 
introducing further STIs once viral 
control was regained. Initial enthusiasm 
for this approach was fuelled by the 
observation that potent Gag-speciﬁ  c 
T helper cell responses develop in 
patients with acute HIV infection 
started on ART, at similar magnitudes 
to those seen in long-term non-
progressors, and to signiﬁ  cantly higher 
levels than are found in untreated 
patients with acute HIV infection or 
ART-treated patients with chronic HIV 
infection [15]. Although some patients 
subjected to STIs after starting ART 
in acute infection were initially able 
to control viraemia and maintain Gag-
speciﬁ  c CD4+ responses off therapy, a 
detailed longitudinal analysis (median 
5.3 years from infection) of this cohort 
showed the effect to be transient, with 
viral breakthrough occurring ultimately 
in most patients, accompanied by a 
similar rate of CD4+ cell loss as that 
seen in early chronic untreated HIV 
infection [16]. It seems, therefore, that 
although the immunological damage 
caused by acute HIV-1 infection may be 
reduced to some extent by early ART, 
this effect is limited to the duration 
of therapy and may not translate into 
long-term beneﬁ  ts. 
Can Early ART Affect Risk of Future 
Disease Progression?
For clinicians to accept early and 
lifelong therapy for HIV-1 infection 
into routine practice, reliable data from 
controlled clinical trials are needed. To 
date, there have been no randomized 
doi:10.1371/journal.pmed.0050103.g001 
Figure 1. Sequence of Events from Acute to Chronic HIV Infection and Potential Interventions to Combat T Cell Exhaustion 
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and adequately powered studies 
addressing the issue of whether early 
ART can affect the risk of future HIV-1 
disease progression. 
A number of observational studies of 
ART used for a limited period in early 
HIV-1 infection present contrasting 
conclusions. One multicentre 
observational study compared surrogate 
markers of disease progression at 
24, 48, and 72 weeks of untreated 
observation in 58 ART-treated patients 
(13 with “acute” infection within two 
weeks of seroconversion and 45 with 
“early” infection within six months of 
seroconversion) and 337 untreated 
patients with primary HIV infection 
[17]. Lower viral loads and higher 
CD4 counts were observed at 24 
weeks following cessation of ART in 
both the acute and early treatment 
groups, although a longer-term beneﬁ  t 
at 72 weeks was less clear. Despite 
these promising results, the variable 
ART duration (median 1.5 years) 
and lack of randomisation, amongst 
other factors, make interpretation 
of this study difﬁ  cult. In contrast, 
short-term ART (for 24 weeks) failed 
to show any beneﬁ  t in CD4 counts 
or viral loads at six months after 
treatment discontinuation in a smaller 
observational study [18]. Enhanced 
interferon-γ and CD107a expression on 
HIV-speciﬁ  c CD8+ T cells at 12 months 
in the treated group did not result in 
lower viral load set points. 
Although these, along with other 
such studies, may hint at the potential 
beneﬁ  ts of using short-term ART 
in acute HIV-1 infection, data are 
needed from adequately powered and 
controlled studies, such as the ongoing 
Short Pulse Anti Retroviral Therapy at 
HIV Seroconversion (SPARTAC) study 
(http://www.ctu.mrc.ac.uk/studies/
spartac.asp). This is an international 
randomised controlled trial comparing 
the effect of combination anti-retroviral 
therapy given for 48 weeks or 12 weeks, 
with a no-intervention arm. 
If, as some of these studies suggest, 
the beneﬁ  ts of early ART are limited 
to the duration of therapy, then the 
question of using longer or even 
continuous periods of treatment must 
be considered. In a recent French 
cohort study where patients initiated 
therapy within 10 weeks of ﬁ  rst acute 
symptoms and continued for a median 
of 2.3 years, 25% of treated patients 
remained aviraemic (more than 50 
copies/ml) as far as 144 weeks after 
cessation of ART [19]. After three years 
of follow-up, only 6% of those in the 
treatment arm met eligibility criteria 
for ART, when compared with 64% of 
patients who did not receive ART in 
the acute stages of infection. An even 
more marked beneﬁ  t from continuous 
treatment instituted within 90 days 
of primary infection was noted in an 
observational study, in which early and 
prolonged treatment was associated 
with signiﬁ  cant protection against rapid 
progression to AIDS and opportunistic 
infections, as well as a substantially 
decreased frequency of more minor 
mucocutaneous and respiratory 
conditions [20]. Nevertheless, HIV-
1 reservoirs in lymphoid tissue and 
latently infected CD4+ T cells persisted, 
and side effects of combination 
therapy were common. Moreover, the 
lack of gut mucosal CD4+ lymphocyte 
reconstitution despite prolonged and 
uninterrupted periods of ART initiated 
in acute HIV-1 infection may suggest 
that even at an early stage much of the 
immunological damage is irreversible 
[21]. 
The possibility that ART may need 
to be started as early as possible and 
continued indeﬁ  nitely raises many 
concerns. How would clinicians 
balance the potential impact on disease 
progression against the cost, drug 
toxicity, and the risk of drug resistance 
entailed by prolonged ART, particularly 
at a time in early HIV-1 infection when 
most patients would be probably be 
asymptomatic without therapy? If it 
is important to treat within days of 
primary infection, how should we best 
identify newly infected patients at the 
optimum time for instituting therapy? 
The need to provide long-term therapy 
for participants in vaccine trials who 
acquire primary HIV-1 infection 
during the trial would have major cost 
and logistic implications that could 
make phase III vaccine trials virtually 
impracticable.
A Way Forward
Probably the best way forward would be 
to develop a therapeutic strategy that 
combines early viral suppression using 
ART with immunotherapy to augment 
HIV-speciﬁ  c immune responses in 
a way that does not expose the host 
immune system to the damaging 
consequences of continued HIV-1 
replication (see Figure 1). Although 
both therapeutic vaccination and 
passive monoclonal antibody infusion 
in this setting have so far failed to show 
absolute beneﬁ  t [22–24], there are 
some data to suggest that therapeutic 
vaccination in chronic HIV-1 infection 
can lead to a restoration of a broad 
and fully functional CTL response 
[25]. In Altfeld and colleagues’ 
study [3], a reliable marker of failing 
CTLs was expression of the molecule 
Five Key Papers in the Field
•  Streeck et al., 2008 [3] Epitope-
speciﬁ  c CD8+ T cells in acute HIV 
infection progressively lose their 
polyfunctional capacity following 
repeated exposure to antigen in acute 
HIV infection, but this exhausted 
phenotype is reversible either with 
anti-retroviral therapy or reduction in 
epitope-speciﬁ  c antigen load due to 
cytotoxic T cell escape mutations.
•  Day et al., 2006 [27] The inhibitory 
receptor PD-1 is signiﬁ  cantly up-
regulated on HIV-speciﬁ  c T cells in 
chronic HIV infection, and expression 
correlates with impaired cytotoxic T 
cell function and predictors of disease 
progression. Blockade of the PD-1 
pathway enhances HIV-speciﬁ  c CD4+ 
and CD8+ cellular function.
•  Mattapallil et al., 2005 [7] 30%–60% 
of CD4+ memory cells in most 
tissues are infected during the 
peak of experimental acute simian 
immunodeﬁ  ciency virus infection in 
macaques, resulting in catastrophic 
early depletion of these cells by direct 
viral infection.
•  Lichterfeld et al., 2004 [14] The loss 
of HIV-speciﬁ  c CD8+ T cell function 
in chronic HIV-1 infection correlates 
with disease progression and is 
critically dependent on IL-2 secretion 
from HIV-speciﬁ  c CD4+ T helper 
cells. This functional deﬁ  cit may be 
reversible with immunotherapeutic 
interventions.
•  Rosenberg et al., 2000 [15] Successful 
treatment of acute HIV infection 
with anti-retroviral therapy leads to 
preservation of HIV-speciﬁ  c CD4+ T 
helper cell responses. Maintenance 
of virus-speciﬁ  c HIV CD8+ and CD4+ 
responses, along with viraemic control, 
can be seen in the short term even 
when therapy is subsequently stopped 
in STIs. PLoS Medicine  |  www.plosmedicine.org 0724 May 2008  |  Volume 5  |  Issue 5  |  e103
programmed death-1 (PD-1), which 
has been associated with “exhausted” 
and dysfunctional T cells in chronic 
infection [26]. Up-regulation of PD-
1 on HIV-speciﬁ  c CTLs correlates 
with plasma viral load [27] and can 
be reversed when viral replication 
is controlled both in chronic and 
acute infection [3,28]. It has recently 
been shown in a murine model of 
lymphochoriomeningitis virus that a 
combination of therapeutic vaccination 
and blockade of PD-1’s interaction 
with its ligand, PD-L1, both enhanced 
the function of responding T cells and 
signiﬁ  cantly improved viral control 
[29]. Perhaps a similar strategy may 
enhance the response to therapeutic 
immunisation in early HIV-1 infection 
and facilitate long-term viral control 
without resorting to lifelong drug 
therapy.  
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